Anesthesia Drugs Ketamine Market: Market Size & Forecast 2026

The Anesthesia Drugs Ketamine market covers ketamine and esketamine formulations marketed primarily for surgical anesthesia, procedural sedation, and acute pain management, with growing off-label and approved use in treatment-resistant depression. The market is estimated at USD 1.1 billion in 2025 and is projected to grow at roughly 16.23% annually through the late 2020s, supported by demand in both inpatient and outpatient surgical settings. Generic injectable ketamine remains the volume backbone of the category, while newer nasal spray and oral dosage forms are reshaping the product mix.

• •Global market size of about USD 1.1 billion in 2025 with double-digit annual growth.
• •Ketamine is used for general anesthesia, procedural sedation, analgesia, and psychiatric indications.
• •Injectable formulations dominate volume; nasal sprays and oral forms are emerging segments.

Surgical procedure volumes continue to climb worldwide as healthcare access expands and outpatient surgery grows, increasing baseline demand for anesthetic agents including ketamine. Parallel momentum is coming from the rapid uptake of ketamine and esketamine in treatment-resistant depression and chronic pain, opening lucrative new therapeutic channels beyond the operating room. Patent expirations of branded products have also widened generic supply, supporting both volume growth and downward pricing pressure on older injectable forms.

• •Rising global surgical volumes and growth of ambulatory surgery centers.
• •Expanding clinical and commercial use of ketamine and esketamine for depression and chronic pain.
• •Increased generic availability and broader healthcare coverage in emerging markets.

By product type, the market is split between injectable ketamine, which holds the largest share, and faster-growing nasal spray and oral formulations tied to psychiatric and chronic pain indications. By application, anesthesia remains the dominant use, while pain management and depression are the most rapidly expanding segments. North America leads revenue contribution due to high surgical throughput, established esketamine adoption, and strong reimbursement, while Asia-Pacific is the fastest-growing region on the back of expanding hospital infrastructure and rising medical tourism.

• •Injectables lead revenue; nasal spray and oral forms are the fastest-growing formats.
• •Anesthesia is the largest application, with depression and pain management gaining share.
• •North America leads the market; Asia-Pacific is the highest-growth region.

What are the recent trends and outlook?

Pipeline activity is focused on novel ketamine and esketamine formulations, including oral tablets and intranasal products targeting depression, PTSD, and chronic pain, which could meaningfully expand the addressable market. Manufacturers are also investing in abuse-deterrent formulations and tighter supply chain controls to address regulatory and public health concerns around misuse. Through the forecast window, the category is expected to outpace the broader anesthesia drugs market, supported by sustained demand for surgical anesthesia and the continued mainstreaming of ketamine-based mental health therapies.

• •Pipeline emphasis on oral and nasal ketamine/esketamine products for psychiatric and pain indications.
• •Greater focus on abuse-deterrent formulations and controlled distribution programs.
• •Market expected to outpace the broader anesthesia drugs category in growth through the late 2020s.